Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
Real-time Estimate Cboe BZX  -  03:24:08 2023-01-27 pm EST
23.49 USD   +4.56%
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/18Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat Muscle-Weakening Disorder
MT
01/18Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about AVIDITY BIOSCIENCES, INC.
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/18Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat..
MT
01/18Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020
DJ
01/18Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o..
PR
01/18Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o..
CI
01/06Avidity Biosciences : January 2023 Corporate Presentation
PU
01/04Wells Fargo Adjusts Price Target on Avidity Biosciences to $55 From $60, Maintains Over..
MT
01/03Insider Sell: Avidity Biosciences
MT
2022Avidity Biosciences, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Avidity Biosciences Prices Common Stock Offering at $17.25 Per Share
MT
2022Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
PR
2022Credit Suisse Adjusts Price Target on Avidity Biosciences to $35 From $33 After 'Largel..
MT
2022Raymond James Adjusts Avidity Biosciences Price Target to $71 From $30, Maintains Stron..
MT
2022Avidity Biosciences Plans Public Offering of Common Stock
MT
2022Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR
2022Sector Update: Health Care Stocks Stage Small Recovery Late
MT
2022Avidity Biosciences : December 2022 Corporate Presentation
PU
2022Sector Update: Health Care Stocks Posting Moderate Gains
MT
2022Top Midday Gainers
MT
2022Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move
MT
2022Sector Update: Health Care Stocks Narrowly Mixed Pre-Bell Wednesday
MT
2022Avidity Biosciences Says Data From Preliminary Assessment of AOC 1001 Shows 'Targeted D..
MT
2022Top Premarket Gainers
MT
2022Avidity Biosciences, Inc. : Regulation FD Disclosure, Other Events, Financial Statements a..
AQ
2022Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ev..
PR
2022Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonst..
CI
2022Avidity Biosciences, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2022Credit Suisse Adjusts Avidity Biosciences' Price Target to $33 From $32, Keeps Outperfo..
MT
2022Raymond James Adjusts Price Target on Avidity Biosciences to $30 From $29, Maintains St..
MT
2022AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
2022Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
2022Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
PR
2022Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
2022Avidity Biosciences, Inc. : Other Events (form 8-K)
AQ
2022Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volu..
CI
2022Avidity Biosciences Launches Phase 1/2 trial of AOC 1044 to Treat Duchenne Muscular Dys..
MT
2022Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne..
PR
2022Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne ..
CI
2022Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annua..
PR
2022Avidity Biosciences, Inc. : Other Events (form 8-K)
AQ
2022Avidity Biosciences, Inc. Plans FORTITUDE Trial of AOC 1020
CI
2022Avidity Biosciences : October 2022 Corporate Presentation
PU
2022Avidity Biosciences Announces the Phase 1/2 FORTITUDE Trial of AOC 1020 in Adults with ..
AQ
2022Avidity Biosciences Launches Phase 1/2 Trial of AOC 1020 in Adults With Facioscapulohum..
MT
2022Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adult..
PR
2022Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults w..
CI
2022Jabil, Hertz rise; Avidity, Provident Financial fall
AQ
2022Sector Update: Health Care Stocks Edging Lower This Afternoon
MT
2022Chardan Research Adjusts Price Target for Avidity Biosciences to $27 From $29, Maintain..
MT
2022Top Midday Decliners
MT
2022Sector Update: Health Care Stocks Slipping Despite Biotechs Maintaining Ea..
MT
2022Avidity Biosciences : September 2022 Corporate Presentation
PU
2022Wall Street Set to Open Higher Ahead of Consumer Confidence, New Home Sales Reports
MT
2022Sector Update: Health Care Stocks Climb Pre-Bell Tuesday
MT
2022Sector Update: Health Care
MT
2022US Futures, Oil Climb Higher
MT
2022Avidity Biosciences Shares Slide on Partial FDA Study Hold
DJ
2022U.S. FDA puts Avidity's muscle disorder drug trial on partial hold
RE
2022Avidity Biosciences Gets FDA Partial Clinical Hold on New Participant Enrollment in MAR..
MT
2022U.S. FDA puts Avidity's muscle disorder drug study on hold
RE
2022Avidity Biosciences, Inc. : Other Events (form 8-K)
AQ
2022Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment i..
PR
2022Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enroll..
CI
2022Avidity Biosciences : FDA Places Partial Hold on AOC 1001 Study
DJ
2022Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy..
PR
2022Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
2022Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
PR
2022Avidity Biosciences : Reports Second Quarter 2022 Financial Results and Recent Highlights ..
PU
2022AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
2022Avidity Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Month..
CI
2022Avidity Biosciences Starts Patient Enrollment in Phase 2 Study of Proposed Neuromuscula..
MT
2022Avidity Biosciences : August 2022 Corporate Presentation
PU
2022Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study
PR
2022Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study
CI
2022Avidity Biosciences Shares Rise After Chardan Research Initiates Coverage
MT
1  2  3  4Next
Upcoming event on AVIDITY BIOSCIENCES, INC.